CVS Health Corporation $CVS Position Reduced by Invesco Ltd.

Invesco Ltd. lowered its stake in CVS Health Corporation (NYSE:CVS) by 1.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 24,019,141 shares of the pharmacy operator’s stock after selling 273,917 shares during the period. Invesco Ltd.’s holdings in CVS Health were worth $1,906,159,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of CVS. Swiss RE Ltd. acquired a new stake in CVS Health during the fourth quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares in the last quarter. Ares Financial Consulting LLC bought a new stake in shares of CVS Health in the 4th quarter valued at approximately $29,000. Dogwood Wealth Management LLC raised its position in shares of CVS Health by 93.7% during the 4th quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after acquiring an additional 179 shares in the last quarter. Finally, GoalVest Advisory LLC bought a new position in CVS Health during the fourth quarter worth $32,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Piper Sandler reiterated an “overweight” rating and set a $113.00 target price on shares of CVS Health in a research note on Monday, June 1st. TD Cowen raised their price target on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Robert W. Baird increased their price objective on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of CVS Health in a report on Friday, May 8th. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.68.

CVS Health Stock Performance

CVS stock opened at $98.26 on Friday. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $102.77. The stock has a market capitalization of $125.38 billion, a price-to-earnings ratio of 43.29, a PEG ratio of 0.97 and a beta of 0.62. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The stock’s fifty day moving average is $88.92 and its two-hundred day moving average is $81.37.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts predict that CVS Health Corporation will post 7.44 EPS for the current year.

Insider Activity at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock worth $323,703,977 in the last 90 days. 0.85% of the stock is owned by company insiders.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.